GUARNERI, Valentina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.922
EU - Europa 8.340
AS - Asia 8.044
SA - Sud America 1.255
AF - Africa 203
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 11
Totale 34.791
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.688
SG - Singapore 2.546
IT - Italia 2.220
CN - Cina 2.151
GB - Regno Unito 1.923
HK - Hong Kong 1.036
BR - Brasile 966
IE - Irlanda 863
VN - Vietnam 810
SE - Svezia 745
DE - Germania 619
FI - Finlandia 412
UA - Ucraina 397
RU - Federazione Russa 303
FR - Francia 282
TR - Turchia 245
KR - Corea 239
IN - India 231
BG - Bulgaria 145
ID - Indonesia 134
BD - Bangladesh 112
CA - Canada 109
AR - Argentina 94
NL - Olanda 91
JP - Giappone 77
MX - Messico 75
IQ - Iraq 69
ZA - Sudafrica 56
PL - Polonia 54
ES - Italia 51
PK - Pakistan 45
AE - Emirati Arabi Uniti 43
CO - Colombia 41
EC - Ecuador 40
PH - Filippine 39
LT - Lituania 33
VE - Venezuela 31
CL - Cile 29
MY - Malesia 29
BE - Belgio 28
UZ - Uzbekistan 28
AT - Austria 24
MA - Marocco 24
PY - Paraguay 24
SA - Arabia Saudita 24
EG - Egitto 22
IR - Iran 20
JO - Giordania 19
TW - Taiwan 19
CZ - Repubblica Ceca 17
HU - Ungheria 16
TH - Thailandia 16
AU - Australia 15
ET - Etiopia 15
GR - Grecia 15
KE - Kenya 15
AZ - Azerbaigian 14
CH - Svizzera 14
TN - Tunisia 14
DZ - Algeria 13
AL - Albania 12
BO - Bolivia 12
NG - Nigeria 12
PT - Portogallo 12
KZ - Kazakistan 11
OM - Oman 11
DO - Repubblica Dominicana 10
LB - Libano 10
RO - Romania 10
CR - Costa Rica 9
NP - Nepal 9
JM - Giamaica 8
RS - Serbia 8
SN - Senegal 8
UY - Uruguay 8
EU - Europa 7
IL - Israele 7
PA - Panama 7
QA - Qatar 7
CI - Costa d'Avorio 6
CY - Cipro 6
MD - Moldavia 6
PE - Perù 6
SI - Slovenia 6
SY - Repubblica araba siriana 6
LV - Lettonia 5
MK - Macedonia 5
BA - Bosnia-Erzegovina 4
BH - Bahrain 4
DK - Danimarca 4
KW - Kuwait 4
LA - Repubblica Popolare Democratica del Laos 4
AO - Angola 3
AP - ???statistics.table.value.countryCode.AP??? 3
BY - Bielorussia 3
HN - Honduras 3
KG - Kirghizistan 3
KH - Cambogia 3
MN - Mongolia 3
NO - Norvegia 3
Totale 34.737
Salva come PNG Salva come JPEG
Città #
Singapore 1.705
Santa Clara 1.682
Fairfield 1.457
Ashburn 1.448
Southend 1.136
Woodbridge 1.093
Hong Kong 1.017
Chandler 916
Houston 885
Dublin 861
Jacksonville 734
San Jose 639
Dearborn 621
Ann Arbor 581
Seattle 544
Wilmington 515
Hefei 509
Beijing 495
Cambridge 483
Nyköping 434
London 379
The Dalles 278
Los Angeles 277
Helsinki 266
Ho Chi Minh City 246
New York 231
Modena 221
Chicago 215
Council Bluffs 211
Seoul 207
Hanoi 200
Milan 181
San Diego 161
Princeton 156
Rome 140
Sofia 139
Eugene 131
Lauterbourg 131
Izmir 126
Moscow 113
Jakarta 103
Munich 103
Salt Lake City 100
Shanghai 95
Dallas 85
São Paulo 84
Buffalo 74
Columbus 67
Naples 61
Des Moines 58
Falls Church 57
Frankfurt am Main 57
Bologna 54
Elk Grove Village 52
Tokyo 51
Orem 50
Tampa 45
Da Nang 43
Turin 43
Dong Ket 41
Norwalk 39
Florence 38
Boardman 37
Bremen 37
Haiphong 37
Bari 35
Denver 35
Phoenix 35
Redwood City 35
Warsaw 34
Guangzhou 32
Atlanta 31
Chennai 30
Fremont 30
Redondo Beach 28
Toronto 28
Mumbai 27
Rio de Janeiro 27
Turku 27
Nanjing 26
Palermo 26
Mexico City 25
Tashkent 25
Curitiba 24
Kunming 24
Amsterdam 23
Genoa 23
Kent 23
Nuremberg 23
San Mateo 23
Brussels 22
Stockholm 22
Johannesburg 21
Belo Horizonte 20
Boston 20
Brooklyn 20
Catania 20
Ottawa 20
Lancaster 19
Montreal 19
Totale 24.177
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.135
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 477
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 424
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 416
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 403
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 377
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 368
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 364
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 364
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 363
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 358
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici 355
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 339
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 334
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 328
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 327
Achievements and unmet needs in the management of advanced ovarian cancer 321
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 319
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas 317
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 313
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 308
Long term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience 305
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 304
Immune characterization of breast cancer metastases: prognostic implications. 302
Detection of microparticles from human red blood cells by multiparametric flow cytometry 300
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 299
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 298
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 298
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors 295
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 294
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 293
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 291
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 287
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 286
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 281
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 280
Trastuzumab containing regimens for early breast cancer. 276
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 264
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 260
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 259
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 255
Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer 255
Downregulation of the Cyclin-Dependent Kinase Inhibitor p27kip1 Might Correlate with Poor Disease-Free and Overall Survival in Inflammatory Breast Cancer 254
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 254
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 253
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 253
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 250
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 249
Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials 245
Biomarkers predicting clinical benefit: fact or fiction? 243
Primary Systemic Therapy in operable breast cancer: clinical data and biological fall-out 242
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 242
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 242
Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial. 240
Timing for starting second-line therapy in recurrent ovarian cancer 239
Biomarker expression and survival after primary chemotherapy for breast cancer. 238
High – dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study 235
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 234
Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. 232
CHER-LOB: PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB, LAPATINIB OR BOTH IN HER2-POSITIVE OPERABLE BREAST CANCER – PRELIMINARY SAFETY REPORT WITH FOCUS ON CARDIAC TOLERABILITY 229
Bone metastases- Pharmacological treatment 226
Trastuzumab-containing regimens for metastatic breast cancer 226
P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 226
Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. 226
Discordant HER2 Total and HER2 Homodimer Levels by HERmark Analysis in Matched Primary and Metastatic Breast Cancer FFPE Specimens. 224
Weekly docetaxel/paclitaxel in pretreated metalistic breast cancer 222
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS 220
Safety of intravenous and oral bisphosphonates and compliance with dosing regimens 219
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support 218
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 217
In response to Body letter to the editor regarding "Safety of intravenous and oral Bisphosphonates and compliance with dosing regimens" 216
The curability of breast cancer and the treatment of advanced disease 216
Bevacizumab treatment for advanced breast cancer. 215
Adding weekly carboplatin to sequential anthracycline and paclitaxel-based chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC) patients: a propensity scorematched study 214
Triple-negative breast cancer: current management and future options. 214
Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives 214
Tumori ginecologici 213
LET-LOB: preoperative letrozole plus lapatinib or placebo in hormone-receptor positive HER2 negative operable breats cancer. Preliminary report of activity and cardiac tolerability 213
LAPATINIB IN ASSOCIAZIONE A CAPECITABINA IN PAZIENTI CON CARCINOMA MAMMARIO METASTTICO HER2 POSITIVO IN PROGRESSIONE DOPO TERAPIA CON TRASTUZUMAB 213
Pazopanib-Induced Heart Failure In A Metastastic Sarcoma Patient: Between Reversible Side Effect and Efficacy 212
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVE: ANALISI PRELIMINARE DELLE TOSSICITA’ 211
Use of Ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients. 208
Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+ breast cancer 206
In response to Jackson letter to the editor regarding "Safety of intravenous and oral bisphosphonates and compliance with dosing regimens" 205
The Next Generation of Biologic Agents: Therapeutic Role in Relation to Existing Therapies in Metastatic Breast Cancer 204
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 198
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2þ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. 198
Operable Breast Cancer: preliminary results of a phase II, double blind, placebo controlled, randomized trial of preoperative chemotherapy +/- gefitinib with biomarkers evaluation 197
Controversies of chemotherapy for the treatment of metastatic breast cancer. 196
CARCINOMI MAMMARI HER2 POSITIVI: CASISTICA DI MODENA 195
Lapatinib or placebo plus letrozole as preoperative treatment of hormone receptor-positive HER2-negative operable breast cancer. Preliminary report of safety and activity of the double-blind randomized phase IIb LET-LOB study 195
Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. 194
ACHIEVEMENTS AND UNMET NEEDS IN THE MANAGEMENT OF EPITHELIAL OVARIAN CANCER 193
The clinical relevance of endocrine therapy induced changes in lipid metabolism in breast cancer patients 193
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer 192
PIK3CA MUTATIONS IN HER2-POSITIVE BREAST CANCER PATIENTS ENROLLED IN THE ADJUVANT RANDOMIZED SHORT-HER STUDY. 192
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation 190
Changes in survival and time to progression in metastatic breast cancer (MBC) patients enrolled into clinical trials from 1983 to 2001 190
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 189
Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial. 189
Totale 26.965
Salva come PNG Salva come JPEG
Categoria #
all - tutte 126.737
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 126.737
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021742 0 0 0 0 0 0 0 0 0 345 240 157
2021/20222.363 61 280 288 108 64 135 149 119 278 202 394 285
2022/20233.462 331 307 174 248 282 375 52 248 1.156 48 137 104
2023/20242.185 98 131 120 134 324 172 169 437 75 115 161 249
2024/20256.106 185 117 106 483 1.214 1.089 323 387 673 314 488 727
2025/202610.666 705 405 882 1.326 1.982 838 1.514 646 1.136 1.232 0 0
Totale 35.023